Indian Journal of Pharmacy & Drugs Studies <pre><strong>Discipline:</strong> Pharmaceutical Sciences <br /><strong>Starting Year:</strong> 2020 <br /><strong>Current volume:</strong> Volume 3<br /><strong>Issue per year:</strong> 4 issues<br /><strong>Indexing: </strong>Google Scholar<br /><strong>E-mail: <a href="" target="_blank" rel="noopener"></a> </strong></pre> Mansa STM publishers en-US Indian Journal of Pharmacy & Drugs Studies A Comparitive Study on Efficacy and Safety of Vildagliptin-Metformin Versus Glimepiride-Metformin in Type 2 Diabetes Mellitus Patients <p><strong>Background:</strong> Inadequate control of blood glucose in patients may lead to micro or macro vascular complications. Metformin is initial drug used to treat diabetes. In case of inefficient glucose control with Metformin, add on therapy is recommended. The motto of our study is to compare efficacy and safety of Vildagliptin – Metformin with Glimepiride –Metformin in type 2 diabetes.</p> <p><strong>Methodology:</strong> A single centre prospective observational study conducted for 6 months in general medicine department at government general hospital, India. A total of 100 patients are recruited in study, divided into 2 groups containing 50 patients, who taking Vildagliptin with Metformin as group 1 and Glimepiride with Metformin as group 2. The data is collected, analyzed, summarized as averages. Figures are represented through graph pad prism by using Microsoft excel.</p> <p><strong>Results:</strong> HbA1C, FBS, RBS parameters are taken as primary and secondary end points to compare groups as per efficacy. Weight gain, hypoglycemia and other GI adverse effects are considered in terms of safety. The difference between values of baseline and final follow up of HbA1C, FBS, RBS are found to be 0.50%, 20mg/dl, 85mg/dl in group 1 (V-M); where as 0.35%, 15mg/dl, 55mg/dl in group 2 (G-M) respectively. 24 ADRs hypoglycemia, weight gain, abdominal pain, muscle tenderness, diarrhoea are observed in group 1 (V-M) group and 46 ADRs are observed in group 2 (G-M).</p> <p><strong>Conclusion:</strong> Vildagliptin-metformin treatment provided favorable glucose control comparable to that of glimepiride-metformin treatment, resulted in better adverse event profiles with lower risks of hypoglycemia, weight gain.</p> Prathap Bingi Kareemulla Shaik B. Himabindu D. Sheklane Khan G. Ramu S. Mahammed Rafi Copyright (c) 2022 Prathap Bingi, Kareemulla Shaik, B. Himabindu, D. Sheklane Khan, G. Ramu, S. Mahammed Rafi 2022-05-09 2022-05-09 1 6 Effect of Glucose Concentrations on the HSA-Hydrochlorothiazide Interaction - Study using Circular Dichroism and Molecular Docking <p>We used circular dichroism (far and near UV) to study the interaction between HSA and hydrochlorothiazide in the absence and presence of glucose at 37ºC. Experimental data were correlated to theoretical analysis through molecular docking simulations. As it is a antihypertensive drug used in the treatment of diabetic hypertensive patients, the ability of hydrochlorothiazide binds to HSA was verified in normoglycemic (containing glucose 80 mg/dl) and hyperglycemic (containing glucose 320 mg/dl) solutions. Results confirm that the binding ability of HCTZ binds to albumin decreases with the GLU concentration increase. This generates a perturbation on the protein structure and an instability condition, which difficulties the bind of HCTZ to the protein binding pocket. It suggests that the adverse effects of HCTZ in hyperglycemic patients may be related to increased levels of free drug in the bloodstream by the decrease of its bind to albumin.&nbsp; ?In this way, effective treatment for diabetic patients with HCTZ is linked to adequate control of the glycemic index.</p> Marilia Marilia Amável Gomes Soares Otávio Augusto Chaves Dilson Silva Darí Cesarín-Sobrinho CELIA MARTINS CORTEZ Copyright (c) 2022 Marilia Marilia Amável Gomes Soares, Otávio Augusto Chaves, Dilson Silva, Darí Cesarín-Sobrinho, CELIA MARTINS CORTEZ 2022-05-09 2022-05-09 7 14